Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 20 July 2006
European patent for Trovax covering 5T4
tumour
He European Patent Office has granted a key patent (No EP1036091), that provides broad protection for Oxford BioMedica's lead product, TroVax
This is one of several granted and pending patents that protect the company's ownership of the 5T4 tumour antigen The granted patent covers immunotherapy products directed against 5T4 and includes specific claims to the use of viral delivery systems in 5T4-targeted vaccines
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
Avian transgenic breakthrough reported
Results are first proof-of-principle with an avian-expressed version of interferon beta; it is expected that the Ova system will be capable of cost-effectively expressing many therapeutic proteins
5T4 is a tumour associated antigen that is expressed on a wide range of tumour types.
A number of published immunohistochemical studies have demonstrated that there is a high incidence of 5T4 expression on colorectal cancer, renal cell carcinoma and breast cancer, amongst others.
5T4 expression is frequently correlated with poor prognosis and metastatic spread.
Overall, 5T4 is present on more than 75% of human solid tumours, yet it is not found on any essential organs.
These characteristics make 5T4 an ideal target for immunotherapy treatment in a wide range of cancer types.
Commenting on the issued patent Oxford BioMedica's chief executive, professor Alan Kingsman said: "The newly granted patent, together with several other granted and pending patents, provide protection for our lead product, TroVax, as well as next generation cancer vaccines based on the 5T4 antigen.
"This positions Oxford BioMedica as one of the leading players in the emerging field of cancer immunotherapy.
"TroVax has potential utility as a treatment for most solids tumours, hence, the potential to be a major commercial opportunity for the company.".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
